Axsome Therapeutics, Inc. (AXSM) Earnings History
Annual and quarterly earnings data from 2013 to 2025
Loading earnings history...
AXSM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
AXSM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 92.6% | -26.5% | -28.7% |
| 2024 | 91.4% | -72.7% | -74.5% |
| 2023 | 90.4% | -85.7% | -88.4% |
| 2022 | 89.6% | -359.3% | -374.0% |
| 2021 | - | - | - |
Download Data
Export AXSM earnings history in CSV or JSON format
Free sign-in required to download data
Axsome Therapeutics, Inc. (AXSM) Earnings Overview
As of May 8, 2026, Axsome Therapeutics, Inc. (AXSM) reported trailing twelve-month net income of -$188M, reflecting +38.6% year-over-year growth. The company earned $-3.68 per diluted share over the past four quarters, with a net profit margin of -28.7%.
Looking at the long-term picture, AXSM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2013.
Axsome Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including INVA ($504M net income, 63.8% margin), SUPN (-$29M net income, -5.4% margin), ACAD ($376M net income, 36.5% margin), AXSM has room to improve margins relative to the peer group. Compare AXSM vs INVA →
AXSM Earnings vs Peers
Earnings metrics vs comparable public companies
AXSM Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$183M | +36.2% | -$169M | $-3.68 | -28.7% | -26.5% |
| 2024 | -$287M | -20.1% | -$281M | $-5.99 | -74.5% | -72.7% |
| 2023 | -$239M | -27.8% | -$232M | $-5.27 | -88.4% | -85.7% |
| 2022 | -$187M | -43.5% | -$180M | $-4.60 | -374.0% | -359.3% |
| 2021 | -$130M | -26.7% | -$125M | $-3.47 | - | - |
| 2020 | -$103M | -50.6% | -$99M | $-2.83 | - | - |
| 2019 | -$68M | -120.7% | -$67M | $-2.05 | - | - |
| 2018 | -$31M | -7.0% | -$33M | $-1.15 | - | - |
| 2017 | -$29M | -6.4% | -$27M | $-1.27 | - | - |
| 2016 | -$27M | -122.8% | -$28M | $-1.42 | - | - |
Full AXSM Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See AXSM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AXSM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AXSM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAXSM — Frequently Asked Questions
Quick answers to the most common questions about buying AXSM stock.
Is AXSM growing earnings?
AXSM EPS is $-3.68, with earnings growth accelerating to +38.6%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-188M.
What are AXSM's profit margins?
Axsome Therapeutics, Inc. net margin is -28.7%, with operating margin at -26.5%. Below-average margins reflect competitive or cost pressures.
How consistent are AXSM's earnings?
AXSM earnings data spans 2013-2025. The accelerating earnings trend is +38.6% YoY. Historical data enables comparison across business cycles.